• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
【24h】

T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.

机译：接种抗独特型抗体105AD7的骨肉瘤患者的T细胞反应类似于CD55。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We assessed T-cell responses in young osteosarcoma patients vaccinated with 105AD7, 1-6 months after having received chemotherapy. 105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein that protects from attack by complement and which is overexpressed on osteosarcoma cells. Seven out of 21 investigated patients made a IFN-gamma T-cell response against the vaccine, 105AD7 as assessed by ELISPOT. Cytokine secretion was analysed using Luminex assays and revealed TNF-alpha and GM-CSF responses not only to the vaccine but also towards the native antigen, CD55, in 5 / 14 (36%) of investigated patients. Importantly, the Luminex assay was found to be more sensitive than the more established T-cell assays (ELISPOT and proliferation assay), since responses towards the native antigen were recorded in this assay. Clinical responses and induction of immune responses to both the anti-idiotype and the native CD55 antigen support the use of CD55 as a target in cancer treatment.
机译：我们评估了接受化疗后1-6个月接种105AD7的年轻骨肉瘤患者的T细胞反应。 105AD7是模仿CD55的人类抗独特型抗体，CD55是一种糖蛋白，可防止补体攻击，并在骨肉瘤细胞中过表达。根据ELISPOT评估，在接受调查的21位患者中，有7位对疫苗105AD7产生了IFN-γT细胞应答。使用Luminex分析法分析了细胞因子的分泌，发现5/14（36％）的患者不仅对疫苗而且对天然抗原CD55都产生TNF-alpha和GM-CSF反应。重要的是，发现Luminex分析比更成熟的T细胞分析（ELISPOT和增殖分析）更敏感，因为在此分析中记录了对天然抗原的反应。针对抗独特型和天然CD55抗原的临床反应和免疫反应的诱导支持将CD55用作癌症治疗的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号